Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41616036.
- Also identified by DOI 10.1371/journal.pmed.1004930 and PMC identifier 12871972.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Antibody-drug conjugates are redefining treatment options in advanced breast cancer, demonstrating efficacy across all breast cancer subtypes. However, their rapid clinical expansion has resulted in several unresolved challenges, including the need for rational sequencing strategies, appropriate and ethical trial design, drug tolerability, and the limitation of mono-national development programs.
Medical subject headings
- Immunoconjugates
- Breast Neoplasms
- Antineoplastic Agents, Immunological